蛋白酶体抑制剂Bortezomib及其在多发性骨髓瘤中的研究进展  

Proteasome inhibitor bortezomib and its development in multiple myeloma

作　　者：古爱虎[1] 汪兴洪[1] 

机构地区：[1]皖南医学院附属弋矶山医院血液内科,芜湖241000

出　　处：《白血病．淋巴瘤》2007年第4期308-311,共4页Journal of Leukemia & Lymphoma

摘　　要：蛋白酶体抑制剂Bortezomib通过抑制蛋白酶体及NF-k B使骨髓瘤细胞凋亡,从Borte- zomib作用分子机制、药理作用、临床前研究、临床疗效评价、耐药及联合用药等方面进行了阐述。Proteasome inhibitor PS-341,a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells,induces apoptosis in multiple myeloma(MM)cells.This review briefly discussed about molecular mechanisms,the pharmacological action,clinical evaluation and clinical evaluation, drug resistance of bortezomib.

关 键 词：多发性骨髓瘤 分子作用机制 蛋白酶体抑制药 

分 类 号：R733.3[医药卫生—肿瘤]